NEW YORK (GenomeWeb) – Investment Bank Cowen and Co. today downgraded shares of GenMark Diagnostics to Market Perform and reduced the price target to $7.25 over concerns with the firm's ability to bring its newest platform to market on time.
Registering provides access to this and other free content.
Already have an account?Login Now.
Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.
Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.